Comparative Pharmacology
Head-to-head clinical analysis: NIACOR versus NICOLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIACOR versus NICOLAR.
NIACOR vs NICOLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and decreasing free fatty acid mobilization from adipose tissue via activation of GPR109A (HM74A) receptor, leading to reduced triglyceride and LDL cholesterol synthesis. It also raises HDL cholesterol by decreasing hepatic clearance of apo A-I.
Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.
NICOLAR (niacin extended-release) is typically initiated at 500 mg orally once daily at bedtime, after a low-fat snack. The dose is increased by 500 mg every 4 weeks as tolerated, up to a maximum of 2000 mg once daily.
None Documented
None Documented
20–45 minutes for immediate-release niacin; terminal half-life of main metabolites (nicotinuric acid) is approximately 1.5–4 hours; short half-life necessitates multiple daily dosing for lipid effects
Terminal elimination half-life is 14-24 hours in adults with normal renal function; clinically, this supports twice-daily dosing. In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to 24-36 hours, requiring dose adjustment.
Renal: 60-88% as unchanged drug and metabolites after oral administration; fecal: <2%
Primarily renal (60-70% as unchanged drug and metabolites), with 10-20% biliary/fecal. Hepatic metabolism to inactive metabolites accounts for ~30% of elimination.
Category C
Category C
Antilipemic agent
Antilipemic agent